Skip to content
Review Open access

Alpha-synuclein pathobiology and therapeutic targeting in Parkinson’s disease

Nov 2026 · ADMET and DMPK · Vol 14 · 0 citations · 142 references

TL;DR

The reviewed evidence indicates that α-Syn pathobiology arises from the interplay of conformational plasticity, molecular interactions, PTMs, and impaired cellular proteostasis, and the need to move beyond reducing α-Syn burden toward selectively preventing pathogenic conformations while preserving its physiological functions.

Abstract

Background and purpose: Alpha-synuclein (α-Syn) is a presynaptic protein involved in synaptic vesicle trafficking, neurotransmitter release, and membrane remodelling. Its misfolding and pathological aggregation are central to Parkinson’s disease (PD) and related synucleinopathies. This review examines how structural changes, post-translational modifications (PTMs), and interactions with proteins, lipids, metal ions, and cellular organelles regulate α-Syn function and contribute to neurodegeneration and evaluates the implications of these mechanisms for biomarker development and therapeutic targeting. Experimental approach: This review synthesizes and critically discusses existing literature on α-Syn structure and physiological functions, molecular interactions, aggregation pathways, cellular toxicity, and the roles of PTMs in protein homeostasis and disease progression. It also evaluates emerging diagnostic approaches, including seed amplification assays and analyses of cerebrospinal fluid, blood, and extracellular vesicles, alongside therapeutic strategies targeting α-Syn aggregation, clearance, and expression. Key results: The reviewed evidence indicates that α-Syn pathobiology arises from the interplay of conformational plasticity, molecular interactions, PTMs, and impaired cellular proteostasis. These processes contribute to mitochondrial dysfunction, lysosomal impairment, neuroinflammation, and the propagation of pathological α-Syn assemblies. Seed amplification assays and other molecular biomarker approaches show promise for improving detection and characterization of synucleino­pathies, while immunotherapies, aggregation inhibitors, gene-based interventions, and strategies that enhance protein clearance represent potential disease-modifying approaches. However, diagnostic standardization and the demonstration of unequivocal clinical efficacy remain important challenges. Conclusion: Integrating α-Syn molecular biology with advances in biomarker development and therapeutic research provides a framework for understanding disease heterogeneity and identifying mechanism-based interventions. This review highlights the need to move beyond reducing α-Syn burden toward selectively preventing pathogenic conformations while preserving its physiological functions. Further validation in clinical studies is essential to establish the diagnostic utility and therapeutic effectiveness of these approaches.

Read PDF

Similar papers

Review Open access Oct 2026

Cellular and systemic modifiers of alpha-synuclein proteostasis

Abstract Ageing is a primary risk factor for neurodegenerative disorders, including Parkinson's disease (PD). As individuals age, their cells become less efficient in maintaining protein homeostasis, leading to an increased likelihood of protein misfolding and aggregation. A hallmark of PD and other synucleinopathies i...

Suzanne Couzijn, Anna P. Ainslie, Alejandro Herron-Bedoya et al. · 0 citations
Review Nov 2026

Gut-Induced Synuclein Propagation: A New Mechanism in Neurodegenerative Disease.

Gut-induced synuclein propagation has emerged as a potential mechanism linking gastrointestinal disturbances with the development and progression of Parkinson disease and related synucleinopathies. These disorders are characterized by progressive accumulation and spreading of misfolded α-synuclein (α-Syn), leading to s...

You Sun, Bo-Wei Li, Ke-Qiang Ye · 0 citations
Open access Oct 2026

Alpha-synuclein and neuromelanin converge to promote Parkinson’s disease pathology

Parkinson’s disease (PD) is defined by the preferential degeneration of neuromelanin (NM)-containing dopamine-producing neurons in the substantia nigra (SN), accompanied by intraneuronal inclusions rich in alpha-synuclein (αSYN). However, the mechanistic relationship between NM accumulation and αSYN pathology remains u...

Alba Nicolau-Vera, Marta González-Sepúlveda, Joana M. Cladera-Sastre et al. · 0 citations
Open access Oct 2026

Extracellular vesicle α-synuclein topology reveals disease-associated conformers in brain and blood.

Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are unified by pathological α-synuclein (αSyn) aggregation, yet diverge in terms of the cellular distribution of pathology and clinical phenotype. Extracellular vesicles (EVs) have emerged as potential mediators or biomarkers o...

Suman Dutta, Amin Atashgaran, Anis Sahoo et al. · 0 citations
Review Open access Oct 2026

Proteostasis (in)action: the role of co-pathologies in neurodegenerative disease

Abstract Clinically distinct neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), share in common progressive neuronal dysfunction and cell death associated with the accumulation of misfolded proteins. Central to these processes are the cellul...

James F. Morley · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.